Literature DB >> 12776223

The prospect for bacteriophage therapy in Western medicine.

Carl R Merril1, Dean Scholl, Sankar L Adhya.   

Abstract

Bacteriophage (phage) have been used for clinical applications since their initial discovery at the beginning of the twentieth century. However, they have never been subjected to the scrutiny--in terms of the determination of efficacy and pharmacokinetics of therapeutic agents--that is required in countries that enforce certification for marketed pharmaceuticals. There are a number of historical reasons for this deficiency, including the overshadowing discovery of the antibiotics. Nevertheless, present efforts to develop phage into reliable antibacterial agents have been substantially enhanced by knowledge gained concerning the genetics and physiology of phage in molecular detail during the past 50 years. Such efforts will be of importance given the emergence of antibiotic-resistant bacteria.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12776223     DOI: 10.1038/nrd1111

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  113 in total

1.  Effects of sequential and simultaneous applications of bacteriophages on populations of Pseudomonas aeruginosa in vitro and in wax moth larvae.

Authors:  Alex R Hall; Daniel De Vos; Ville-Petri Friman; Jean-Paul Pirnay; Angus Buckling
Journal:  Appl Environ Microbiol       Date:  2012-06-01       Impact factor: 4.792

2.  Personalized Therapeutic Cocktail of Wild Environmental Phages Rescues Mice from Acinetobacter baumannii Wound Infections.

Authors:  James M Regeimbal; Anna C Jacobs; Brendan W Corey; Matthew S Henry; Mitchell G Thompson; Rebecca L Pavlicek; Javier Quinones; Ryan M Hannah; Meron Ghebremedhin; Nicole J Crane; Daniel V Zurawski; Nimfa C Teneza-Mora; Biswajit Biswas; Eric R Hall
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

3.  Impact of phages on two-species bacterial communities.

Authors:  W R Harcombe; J J Bull
Journal:  Appl Environ Microbiol       Date:  2005-09       Impact factor: 4.792

4.  Bacteriophage P1 in retrospect and in prospect.

Authors:  Michael B Yarmolinsky
Journal:  J Bacteriol       Date:  2004-11       Impact factor: 3.490

Review 5.  Bacteriophage therapy against Enterobacteriaceae.

Authors:  Youqiang Xu; Yong Liu; Yang Liu; Jiangsen Pei; Su Yao; Chi Cheng
Journal:  Virol Sin       Date:  2015-02-03       Impact factor: 4.327

6.  Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy.

Authors:  Timothy K Lu; James J Collins
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-02       Impact factor: 11.205

7.  Predicting in vivo efficacy of therapeutic bacteriophages used to treat pulmonary infections.

Authors:  Marine Henry; Rob Lavigne; Laurent Debarbieux
Journal:  Antimicrob Agents Chemother       Date:  2013-09-16       Impact factor: 5.191

8.  The effects of staphylococcal bacteriophage lysates on cancer cells in vitro.

Authors:  Krystyna Dabrowska; Grzegorz Skaradziński; Aneta Kurzepa; Barbara Owczarek; Maciej Zaczek; Beata Weber-Dabrowska; Joanna Wietrzyk; Magdalena Maciejewska; Paulina Budynek; Andrzej Górski
Journal:  Clin Exp Med       Date:  2009-09-25       Impact factor: 3.984

9.  Therapy of experimental pseudomonas infections with a nonreplicating genetically modified phage.

Authors:  Steven Hagens; André Habel; Uwe von Ahsen; Alexander von Gabain; Udo Bläsi
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

10.  Ultrasensitive Qbeta phage analysis using fluorescence correlation spectroscopy on an optofluidic chip.

Authors:  M I Rudenko; S Kühn; E J Lunt; D W Deamer; A R Hawkins; H Schmidt
Journal:  Biosens Bioelectron       Date:  2009-04-16       Impact factor: 10.618

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.